Clincosm LogoSign in Get a demo

Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel

Sponsor
Hellenic Cooperative Oncology Group (Other)
Overall Status
Completed
CT.gov ID
NCT05486247
Collaborator
(none)
32
Enrollment
86.8
Actual Duration (Months)

Study Details

Study Description

Brief Summary

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    32 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Molecular Characterization of Gliomas Using a Broad NGS Panel
    Actual Study Start Date :
    Feb 4, 2015
    Actual Primary Completion Date :
    Dec 1, 2021
    Actual Study Completion Date :
    May 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel [April 2019 - December 2021]

      The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Diagnosis of high grade glioma based on tissue biopsy

    Exclusion Criteria:

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hellenic Cooperative Oncology Group

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Rania Romanidou, Dr Ourania Romanidou, Hellenic Cooperative Oncology Group
    ClinicalTrials.gov Identifier:
    NCT05486247
    Other Study ID Numbers:
    • NGSGLIOMA
    First Posted:
    Aug 3, 2022
    Last Update Posted:
    Aug 3, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Rania Romanidou, Dr Ourania Romanidou, Hellenic Cooperative Oncology Group
    Molecular profile
    Mutational status
    Additional relevant MeSH terms:
    Glioma

    Study Results

    No Results Posted as of Aug 3, 2022